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Rehospitalization for Heart Failure
Problems and Perspectives
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With a prevalence of 5.8 million in the United States alone, heart failure (HF) is associated with high morbidity,
mortality, and healthcare expenditures. Close to 1 million hospitalizations for heart failure (HHF) occur annually,
accounting for over 6.5 million hospital days and a substantial portion of the estimated $37.2 billion that is
spent each year on HF in the United States. Although some progress has been made in reducing mortality in
patients hospitalized with HF, rates of rehospitalization continue to rise, and approach 30% within 60 to 90 days
of discharge. Approximately half of HHF patients have preserved or relatively preserved ejection fraction (EF).
Their post-discharge event rate is similar to those with reduced EF. HF readmission is increasingly being used as
a quality metric, a basis for hospital reimbursement, and an outcome measure in HF clinical trials. In order to
effectively prevent HF readmissions and improve overall outcomes, it is important to have a complete and longi-
tudinal characterization of HHF patients. This paper highlights management strategies that when properly imple-
mented may help reduce HF rehospitalizations and include adopting a mechanistic approach to cardiac abnor-
malities, treating noncardiac comorbidities, increasing utilization of evidence-based therapies, and improving
care transitions, monitoring, and disease management. (J Am Coll Cardiol 2013;61:391–403) © 2013 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.038H
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aHeart failure (HF) is the most common cause of hospital-
ization in patients over the age of 65, resulting in 6.5 million
hospital days in the United States annually (1). In outpa-
tients with chronic HF, a hospitalization is one of the
strongest prognostic predictors for increased mortality. Un-
planned readmissions also have a heavy associated financial
burden and cost Medicare $17.4 billion annually, with HF
being the largest contributor (2). Worsening chronic HF
resulting in hospitalization may be associated with cardiac
and/or renal injury that can contribute to progression of HF.
Heart failure is not a disease, but a manifestation of
diverse cardiac and noncardiac abnormalities (3). A distinc-
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t2012, accepted September 11, 2012.tion should be made between outcomes in outpatients with
chronic HF and patients with hospitalization for HF
(HHF). In outpatients with HF, prognosis has significantly
improved in the last 20 years, given the advent of therapies
such as angiotensin-converting enzyme (ACE) inhibitors/
angiotensin receptor blockers (ARBs), beta-blockers, min-
eralocorticoid receptor antagonists (MRAs), and implantable
cardioverter-defibrillator (ICD)/cardiac resynchronization therapy
devices (CRT). By contrast, patients with HHF continue to
have a mortality and readmission rate approaching 15% and
30%, respectively, within 30 to 60 days post-discharge (3).
HF patients have only been characterized in the past
ecade through registries and trials (4,5), which highlighted
he fact that the clinical course and prognosis of these
atients differs from that of outpatients with chronic HF.
atient Characterization and Clinical Course
efinition. HHF is defined as new-onset or worsening
gradual or rapid) signs and symptoms of HF that require
rgent therapy and result in hospitalization (3). HHF
omprises patients with: 1) worsening chronic HF (80%);
) de novo HF (15%); and 3) advanced or end-stage HF
5%). Traditionally, HHF was not viewed as a distinct
ntity, but rather a more severe manifestation of chronic
F. However, the majority of HHF patients do not have
dvanced HF because they respond well to in-hospital
herapies. They can be distinguished from patients with
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Rehospitalization for Heart Failure January 29, 2013:391–403chronic HF by having very ab-
normal hemodynamic, neuro-
hormonal, and electrolyte abnor-
malities, often associated with
troponin release and rapidly
worsening renal function (6). In
contrast to outpatients, HHF pa-
tients have a very high post-
discharge mortality and rehospi-
talization rate that has not
improved in the last 2 decades
despite all the available therapies
(5,7) (Fig. 1). Unfortunately, tri-
als conducted to date have fo-
cused on improving signs and
symptoms during hospitalization
with short-term therapies, rather
than improving post-discharge
outcomes (8–10).
Patient characteristics. Ap-
proximately 50% of HHF patients
have preserved or relatively pre-
served ejection fraction (HFpEF).
Table 1 depicts characteristics of
patients with HFpEF and with
HF with reduced ejection frac-
tion (HFrEF) (4).
The majority of patients are
normotensive or hypertensive at
resentation (11). Irrespective of ejection fraction (EF), the
ajority have signs of congestion such as dyspnea, jugular
enous distention, and edema. Almost all are initially
reated with intravenous diuretics, and few receive intrave-
ous vasodilators or inotropes.
utcomes
ength of stay. Among HHF patients, the median length
f stay is 4.0 days (25th to 75th interquartile range, 3.0 to
.0 days), and mean length of stay is 6.4  85.2 days in the
nited States (4).
ehospitalization at 30 days. Among Medicare beneficia-
ies hospitalized with HF, 27% are rehospitalized within
0 days, and 37% of these rehospitalizations are for HF
2,12,13). In the EVEREST (Efficacy of Vasopressin
ntagonism in Heart Failure Outcome Study With
olvaptan) trial, 24% of HHF patients randomized in the
nited States were readmitted within 30 days of dis-
harge (5) despite the fact that the majority were treated
ith evidence-based treatments and had early post-
ischarge visits. In this trial, 48% of all hospitalizations
ere HF related, 14% were cardiovascular, and 38%,
oncardiovascular (Fig. 2). These numbers were consid-
erably different outside of the United States and varied by
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin
receptor blocker
CAD  coronary artery
disease
COPD  chronic
obstructive pulmonary
disease
CRT  cardiac
resynchronization therapy
ED  emergency
department
EF  ejection fraction
HFpEF  heart failure with
preserved ejection fraction
HFrEF  heart failure with
reduced ejection fraction
HHF  hospitalization for
heart failure
ICD  implantable
cardioverter defibrillator
LV  left
ventricle/ventricular
MRA  mineralocorticoid
receptor antagonistgeographical location (2,14).Rehospitalization beyond 30 days. In the OPTIMIZE-HF
(Organized Program to Initiate Lifesaving Treatment in
Hospitalized Patients With Heart Failure) registry, rates of
rehospitalization were 30% at 60 to 90 days post-discharge
(4). The rates of rehospitalization in patients with HFpEF
were similar when compared with those with HFrEF (4,15).
Approximately half of the rehospitalizations were not re-
lated to HF (5). Table 2 depicts characteristics of patients
in the United States rehospitalized within 3 months
post-discharge.
Mortality. In-hospital mortality for HHF is 2% to 7%, but
as high as 20% in patients with severe renal impairment
and/or low systolic blood pressure (representing 2% to 5% of
all HHF patients). Mortality rates 60 to 90 days post-
discharge vary from 5% to 15% (4,5). In the EVEREST
trial, 40% of post-discharge deaths were from HF, and 30%
were related to sudden cardiac death (5) (Fig. 3). Patients
with HFpEF have similar rates of post-discharge mortality
compared with those with HFrEF, but the mode of death
may differ (4,15).
Prognostic markers. Predictors of prognosis include a
systolic blood pressure 120 mm Hg at presentation
(11,16), presence of coronary artery disease (CAD) (17),
hyponatremia (18), renal impairment (6), troponin release
(17,19), and ventricular dyssynchrony (QRS duration 120
ms) (20). In the early post-discharge period, changes in
body weight, signs and symptoms of congestion (21),
worsening renal function, and elevation of natriuretic pep-
tides are correlated with readmissions (22) (Table 3).
Predictors for readmission are different than those for
mortality; systolic blood pressure predicts mortality, whereas
an increase in body weight predicts rehospitalization (11,23)
(Fig. 4).
Although biomarkers may be useful in helping with
diagnosis, prognosis, and management of HHF, their in-
terpretation should account for the presence of cardiac and
noncardiac comorbidities such as CAD, atrial fibrillation,
chronic obstructive pulmonary disease (COPD), and renal
dysfunction (24).
Precipitants of rehospitalization. Precipitants for HHF
(25) include cardiac factors such as myocardial ischemia,
atrial fibrillation, and uncontrolled hypertension; noncar-
diac factors, such as exacerbation of COPD and infec-
tions (Table 4); patient-related factors, such as medica-
tion nonadherence, dietary indiscretion, and drug and
alcohol abuse; iatrogenic factors, such as use of nonsteroi-
dal anti-inflammatory drugs; and system-related factors,
including inadequate access to follow-up care and med-
ications, limited access to low-sodium foods, and poor
transitions of care (Table 5).
Pathophysiology Leading to Rehospitalization
Congestion. The main reason for HF readmission is con-
gestion and not low cardiac output (26). However, conges-
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January 29, 2013:391–403 Rehospitalization for Heart Failuretion related to high left ventricular (LV) filling pressures
may be the result of diverse cardiac abnormalities (e.g.,
myocardial infarction, valvular disease, arrhythmias). Often,
congestion develops gradually before admission. In the
outpatient setting, patients may have elevated LV filling
pressures in the absence of congestion (dyspnea, jugular
venous distention, or edema). This subclinical congestion
(26) may precede clinical congestion by days to weeks or be
present at discharge (22,27).
Elevated LV filling pressures may contribute to progres-
sion of HF by causing subendocardial ischemia/injury (26),
ltered LV geometry resulting in secondary mitral regurgi-
ation, further activation of the renin-angiotensin-
ldosterone system, stimulation of inflammatory mediators,
nd worsening renal function due to increased venous
ressures.
Because congestion is the single most important contrib-
tor to readmission, it is important to recognize that many
atients after discharge may be “flying under the radar,”
ithout clinical congestion, but with elevated LV filling
ressures often reflected by the high levels of natriuretic
Figure 1 Hospitalization for HF in the United States
Secular trends for length of stay, discharge disposition, unadjusted mortality, and
heart failure (HF) between 1993 and 2006. Due to their small size, error bars (95
with permission, from Bueno et al. (77).eptides (22). (Assessment
At presentation, utilizing the 6-axis model (28), patients can
e appropriately managed on the basis of limited data. The
-axis model is a set of easily obtainable parameters (clinical
everity, de novo or chronic HF, blood pressure, comorbidi-
ies, precipitants, and heart rate/rhythm), each with inde-
endent clinical relevance. Severity of HF at the presenta-
ion does not correlate with post-discharge outcomes.
Once patients are stabilized, their cardiac structure and
unction should be evaluated (28). Echocardiography
ith Doppler should define LV function, left atrial size,
resence and severity of mitral regurgitation, pulmonary
rterial pressures, and wall motion abnormalities. The
xtent and severity of CAD should be assessed by invasive
nd noninvasive testing. Viable, but dysfunctional, myo-
ardium should be assessed, using cardiac magnetic
esonance imaging, dobutamine stress echocardiography,
ingle-photon emission computed tomography, or posi-
ron emission tomography, and will indicate the potential
or myocardial recovery in patients with or without CAD
y all-cause readmission rates in Medicare fee-for-service patients hospitalized for
dence intervals) are included within the size of the data markers. Reproduced,30-da
% confi29,30).
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Rehospitalization for Heart Failure January 29, 2013:391–403Baseline Patient Characteristics, HF History, and Findings on Admission by Ventricular FunctionTable 1 Baseline Patient Characteristics, HF History, and Findings on Admission by Ventricular Function
Characteristics at Admission
Patients With LVSD
(n  20,118)
Patients With PSF
(n  21,149)
p Value
(LVSD vs. PSF)
Patients With 40%
< EF <50%
(n  7,321)
Patients With
EF >50%
(n  10,072)
p Value
(40% < EF
<50% vs.
EF >50%)
Demographics
Age, yrs 70.4 14.3 75.1 13.1 0.0001 74.3 13.0 75.6 13.1 0.0001
Male 62 38 0.0001 48 32 0.0001
Caucasian 71 77 0.0001 78 77 0.086
African American 21 15 0.0001 15 15 0.88
Medical history
Diabetes, insulin-treated 15 17 0.0001 18 16 0.013
Diabetes, noninsulin-treated 24 26 0.009 26 25 0.418
Hypertension 66 76 0.0001 74 77 0.0001
Hyperlipidemia 34 32 0.0001 35 31 0.0001
Atrial arrhythmia 28 33 0.0001 33 32 0.179
Vital signs on admission
Body weight, kg 78.5 [65.8–94.0] 78.9 [64.0–97.5] 0.019 79.4 [65.0–97.5] 78.0 [63.5–97.1] 0.002
Heart rate, beats/min 89 22 85 21 0.0001 86 21 84 21 0.0001
SBP, mm Hg 135 31 149 33 0.0001 147 33 150 33 0.0001
DBP, mm Hg 77 19 76 19 0.0001 77 19 75 19 0.0001
Etiology
Ischemic 54 38 0.0001 49 32 0.0001
Hypertensive 17 28 0.0001 22 31 0.0001
Idiopathic 18 21 0.0001 18 23 0.0001
Findings on admission
Acute pulmonary edema 3 2 0.27 2 3 0.362
Chest pain 23 24 0.512 24 24 0.618
Uncontrolled hypertension 9 12 0.0001 11 12 0.075
Dyspnea at rest 44 44 0.194 46 44 0.022
Dyspnea on exertion 63 62 0.206 62 62 0.719
Rales 63 65 0.001 67 63 0.0001
Lower extremity edema 62 68 0.0001 68 68 0.211
Jugular venous pulsation 33 26 0.0001 32 29 0.0005
Left ventricular EF 24.3 7.7 54.7 10.2 0.0001 45.0 4.0 61.8 7.0 0.0001
Laboratory values
Serum sodium, mEq/l 137.7 4.6 137.9 4.8 0.0001 137.9 4.7 137.8 4.8 0.09
Serum creatinine, mg/dl 1.4 [1.1–1.9] 1.3 [1.0–1.8] 0.0001 1.3 [1.0–1.9] 1.2 [1.0–1.8] 0.0001
Serum hemoglobin, g/dl 12.5 2.0 11.9 2.0 0.0001 11.9 2.0 11.8 2.0 0.0001
BNP, pg/ml 1,170.0 [603.0–2,280.0] 601.5 [320.0–1,190.0] 0.0001 757.0 [400.0–1,460.0] 537.0 [287.0–996.5] 0.0001
Troponin I, ng/ml 0.1 [0.1–0.3] 0.1 [0.0–0.3] 0.0001 0.1 [0.1–0.3] 0.1 [0.0–0.3] 0.0001
Medications on admission
ACE inhibitor 45 36 0.0001 38 34 0.0001
ARB 11 13 0.0001 12 14 0.0001
Amlodipine 5 10 0.0001 9 11 0.0001
Aldosterone antagonist 10 5 0.0001 6 4 0.0001
Beta-blocker 56 52 0.0001 54 50 0.0001
Loop diuretic 63 58 0.0001 59 57 0.039
Digoxin 30 17 0.0001 19 15 0.0001
Aspirin 42 38 0.0001 41 36 0.0001
Antiarrhythmic 13 8 0.0001 10 8 0.0001
Hydralazine 3 3 0.021 3 3 0.346
Nitrate 22 21 0.013 23 20 0.0001
Statin* 40 39 0.021 41 37 0.0001
Values are mean SD, %, or median [interquartile range]. Reproduced, with permission, from Fonarow et al. (4). *Statin use among patients with coronary artery disease, cerebrovascular disease/transient
ischemic attack, diabetes, hyperlipidemia, or peripheral vascular disease.ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BNP  B-type natriuretic peptide; DBP  diastolic blood pressure; EF  ejection fraction; HF  heart failure; LVSD  left
entricular systolic dysfunction; PSF  preserved systolic function; SBP  systolic blood pressure.
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January 29, 2013:391–403 Rehospitalization for Heart FailureBefore hospital discharge, signs and symptoms of con-
gestion should be reassessed both at rest and during activity
(31), and natriuretic peptide levels measured (32). Patient
Figure 2 Rehospitalization After an Admission for HF
The number of hospitalizations within 30 days, 31 to 60 days, and more than
60 days after a hospitalization for heart failure (HF) in the EVEREST (Efficacy of
Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan) trial.
The reasons for hospitalization are represented in each bar. Non-CV hospital-
ization  noncardiovascular hospitalization; Non-HF CV hospitalization  non-
heart failure cardiovascular hospitalization. Figure reproduced, with permission,
from O’Connor et al. (5).
Select Baseline Characteristics for U.S. EVEREST Patients (n  1,Table 2 Select Baseline Characteristics for U.S. EVEREST Pati
Variable CV Hospitalization <3 Months CV H
Patients 440 (38.6)
Age, yrs 69 [59–77]
Male 323 (73.4)
Previous HF hospitalization 383 (87.2)
CAD 353 (80.2)
Previous MI 257 (58.4)
Mitral valve disease 253 (57.8)
Diabetes 239 (54.3)
Renal insufficiency 247 (56.3)
COPD 94 (21.4)
Orthopnea 296 (70.5)
Supine SBP, mm Hg 113.5 17.7
Supine DBP, mm Hg 66 12.4
LVEF, % 23.3 8.6
QRS, ms 136.2 37.3
Sodium, mEq/l 138.4 4.5
BUN, mg/dl 39.7 22.4
Creatinine, mg/dl 1.6 0.5
Aldosterone, ng/dl 22.6 30.6
AVP, pg/dl 2.8 [2.8–6.7]
BNP, pg/dl 1,356.2 [622.5–2,454.6] 1
N-terminal proBNP, pg/dl 7,170 [3,381–13,507] 4
Values are n (%), median (interquartile range), or mean  SD. The baseline characteristics for the
shown by occurrence and time of cardiovascular hospitalization.AVP  arginine vasopressin; BUN  blood urea nitrogen; CAD  coronary artery disease; COPD  c
Antagonism in Heart Failure Outcome Study With Tolvaptan; LVEF  left ventricular ejection fraction; MInd family education and assurance that the patient is
eceiving all evidence-based therapies are essential (1).
educing Readmissions
anaging congestion. Prevention of clinical and subclin-
cal congestion is essential to reduce rehospitalization rates.
odium restriction remains the cornerstone of fluid man-
gement, especially in the post-discharge period. Loop
iuretic therapy remains the mainstay of congestion man-
gement despite the advent of novel and largely untested
herapies such as ultrafiltration, vasopressin antagonists, and
denosine-blocking agents (33). Because the goal is to
educe intravascular volume, it is important to consider the
echanism of fluid removal, composition of fluid removed,
nd whether the reduction is intravascular or extravascular.
lthough diuretic therapy may worsen renal function during
ospitalization, this should not deter aggressive fluid man-
gement, as renal impairment may be transient and not
epresent kidney injury (6). In fact, ACE inhibitors or
RBs may show mortality benefit even though they may
lso worsen renal function (34).
Most patients experience a significant improvement in
linical congestion during hospitalization, but many have
ersistent evidence of subclinical congestion. Elevated na-
riuretic peptide levels at the time of discharge serve as a
oor prognostic feature (22) and may warrant further
nvestigation into persistent congestion via dynamic testing
orthopnea, 6-min walk, and so on). Initial and mainte-
[27.6%])(n  1,139 [27.6%])
lization 3–12 Months No CV Hospitalization at 1 Year p Value
403 (35.4) 296 (26.0)
9 [59–77] 66 [55.5–77] 0.101
308 (76.4) 218 (73.6) 0.555
313 (78.1) 214 (72.5) 0.001
323 (80.3) 206 (69.8) 0.001
233 (58.1) 133 (44.9) 0.001
192 (48.1) 122 (41.5) 0.001
205 (51) 146 (49.3) 0.378
184 (45.8) 101 (34.1) 0.001
65 (16.2) 54 (18.2) 0.151
232 (59.3) 188 (66.2) 0.004
18.3 19.9 119.6 20.5 0.001
67.4 13.2 68.9 13.3 0.01
24.8 8.5 25.6 8.4 0.001
33.5 35.9 124.2 33.1 0.001
139 4 139.4 4.4 0.009
34 17.7 29.4 15.7 0.001
1.5 0.5 1.4 0.5 0.001
14.3 17 12.7 13.3 0.001
8 [2.8–6.3] 2.8 [2.8–5.7] 0.043
5 [457.2–2,072.9] 695.2 [243.7–1,439.2] 0.001
5 [2,070–11,942] 3,710 [1,752–6,934] 0.001
EREST patients who were followed for or hospitalized during the first year after randomization are139ents
ospita
6
1
1
2.
,059.
,962.
U.S. EVhronic obstructive pulmonary disease; CV  cardiovascular; EVEREST  Efficacy of Vasopressin
 myocardial infarction; other abbreviations as in Table 1.
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Rehospitalization for Heart Failure January 29, 2013:391–403nance diuretic dosing strategies (35) should be guided by
supine and orthostatic blood pressure measurement and
renal function (32,35). Metolazone, a long-acting thiazide-
like diuretic, may be used in patients who are unresponsive
to initial therapies, but carries a significant risk of hypona-
tremia. MRAs may be particularly useful, given recent data
demonstrating that they significantly reduce the early hos-
pitalization rate (36,37). For patients presenting with hy-
ponatremia, relative hypotension, and/or impaired renal
function, tolvaptan, a vasopressin antagonist, should be
considered although its long-term effects remain to be
determined (38,39).
Nondiuretic therapies. Despite improving national trends,
a gap persists between cardiovascular guideline recommen-
dations (1) and clinical practice in HF (7). This gap has
een the target of current performance measures (40).
owever, the current performance measures may not be
ufficient to improve post-discharge outcome of such a
omplex condition (40). Patients with HFrEF should re-
eive recommended doses of ACE inhibitors/ARBs, beta-
lockers, and MRAs. Data regarding nondiuretic therapies
re limited in the setting of hospitalization in patients with
FpEF. Although there is ample evidence of long-term
eneficial effects of MRAs on survival and hospitalization
ates in HFrEF (41,42), a recent study reported that under
ne-third of eligible patients who were hospitalized with
F received MRAs at discharge (42). This may be related
o the need to monitor serum potassium and renal function
n patients receiving these agents.
Hydralazine/nitrate therapy is recommended for African
mericans with HFrEF (43). Candidates for revasculariza-
Figure 3 Mode of Death After a HHF
The number of deaths within 30 days, 31 to 60 days, and more than 60 days
after a hospitalization for heart failure in the EVEREST (Efficacy of Vasopressin
Antagonism in Heart Failure Outcome Study With Tolvaptan) trial. Their mode of
death is represented in each bar. HF death  death from heart failure; SCD 
sudden cardiac death. Reproduced, with permission, from O’Connor et al. (5).ion should be identified, and in appropriate patients,iscussions regarding device therapies (ICDs and CRT)
hould occur (1). Although not tested, digoxin possesses
any desirable attributes for patients with HHF, given its
emodynamic, neurohormonal, and electrophysiological ef-
ects (44). The DIG (Digitalis Investigators Group) trial
emonstrated that digoxin, when added to diuretics and
CE inhibitors in patients with chronic HF in sinus
hythm, decreases hospitalizations without adversely affect-
ng survival (45). The DIG ancillary trial assessed the effects
f digoxin in patients with HFpEF and showed reduction in
F-related hospitalizations only at 2 years of follow-up
46). It is important to note that data are currently lacking
egarding the utility of digoxin in HHF patients. Potentially
eleterious agents in HF that are viewed as benign by
atients, such as nonsteroidal anti-inflammatory drugs and
asal decongestants, should be avoided.
mechanistic approach. Because HF can be caused by
iverse cardiac abnormalities, every attempt should be made
o identify specific cardiac abnormalities that contribute to
F (Fig. 5).
yocardium. In patients with HFrEF, the identification
f potentially recoverable (viable, but dysfunctional) myo-
ardium is important for prognostic and therapeutic reasons
n patients with and without CAD (29,30). Data from a
arge quality improvement study revealed a third of patients
howed an improvement in LVEF from 25% to 46% over a
4-month period after a multidimensional practice-specific
reatment approach (47). Clinical decision support tools,
hart audits with regular feedback, and other interventions
ere used to optimize adherence to guideline recommen-
ations in this study. Potential for myocardial recovery was
raditionally performed only in patients with CAD to detect
tunned or hibernating myocardium to determine utility of
evascularization. However, myocardial viability has been
hown to predict recovery even in patients without CAD
29,30).
oronary arteries. HHF patients with CAD are at higher
isk for mortality and rehospitalization than those without
Prognostic Value of Individual Elements of the1-Week Follow-Up ExaminationTable 3 Prognostic Val e of Individual El ments of the1-Week Follow-Up Examination
1-Week Follow-Up
Components*
IDI Increase
(%)
p Value for IDI
Increase†
BNP 5.5 0.001
KCCQ 3.2 0.001
Pedal edema 2.9 0.001
Rales 2.2 0.001
Anemia 1.5 0.001
GFR, ml/min 1.0 0.001
SBP, mm Hg 0.6 0.005
Serum sodium, mmol/l 0.2 0.08
Heart rate, beats/min 0.03 0.48
*From highest to lowest IDI increase. †Comparison to model with history (age, sex, race,
comorbidities, left ventricular ejection fraction)/discharge medications only. Reproduced, with
permission, from Dunlay et al. (21).GFR  glomerular filtration rate; IDI  integrated discrimination improvement; KCCQ 
Kansas City Cardiomyopathy Questionnaire; other abbreviations as in Table 1.
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January 29, 2013:391–403 Rehospitalization for Heart FailureCAD (17). Although there is a very low rate of clinical
schemic events after discharge (5), progression of CAD
may contribute to rehospitalization and mortality. It is
plausible that ischemic events may not be clinically recog-
nized due to atypical presentations and significant electro-
cardiographic abnormalities. Myocardial injury, as evi-
denced by troponin release during or after discharge (19),
may contribute to HF progression and sudden death.
Patients with CAD may benefit from HMG-CoA reduc-
tase inhibitors, antiplatelet/antithrombotic agents, and re-
vascularization procedures (17,19).
Electrical system. Although reducing the heart rate with
ivabradine is beneficial in chronic HF (48), the optimal
eart rate in HHF has not been determined. Patients with
trial fibrillation should receive anticoagulation and rate
ontrol with beta-blockers and digoxin (49). Ventricular
yssynchrony, defined by a wide QRS complex, is common
n HHF patients with reduced EF (20,50). Once optimized
on medical therapy, this subset of patients may benefit from
CRT after hospital discharge. The role of ICD implanta-
tion in patients with HHF remains to be determined (51).
Figure 4 Relationship Between Increase in Body Weight and R
Body weight (BW) changes and outcomes. Post-discharge changes in BW are plott
remote clinic visit prior to the event in patients with events at 60, 120, and 180 d
changes in BW in patients with no event and in patients at the visit prior to the eve
Precipitating Factors and Multivariate Risk-Adjusted In-Hospital CliTable 4 Precipitating Factors and Multivariate Risk-Adjusted In
Factor n Adjuste
Ischemia/acute coronary syndrome 7,155
Arrhythmia 6,552
Nonadherence to diet 2,504
Uncontrolled hypertension 5,220
Nonadherence to medications 4,309
Pneumonia/respiratory process 7,426
Worsening renal function 3,304
Other 6,171Reproduced, with permission, from Fonarow et al. (25).
CI  confidence interval; LOS  length of stay; OR  odds ratio.Valves. Secondary mitral regurgitation from chronic LV di-
lation is common in HFrEF. It remains unclear whether this is
a marker of severity of LV dysfunction or a therapeutic target.
Systemic hypertension and pulmonary hypertension. Be-
cause systemic hypertension can contribute to progression of
HF, strict management with appropriate therapies is war-
ranted. A significant number of HHF patients, particularly
those with HFpEF, also have pulmonary venous hypertension.
These patients are at higher risk and thus may require closer
monitoring (52). Treatment modalities for patients with co-
morbid pulmonary hypertension remain investigational.
Noncardiac comorbidities. A significant number of HHF
patients have COPD, diabetes, obstructive sleep apnea, and
renal impairment (53–55). Although data are lacking on the
treatment of HHF with specific comorbid conditions,
addressing these noncardiac comorbidities may serve as an
adjunct to current HHF management approaches.
Heart failure with preserved ejection fraction. Approxi-
mately 50% of HHF patients have HFpEF (15,56). Because
evidence-based treatment strategies that are effective in
patients with reduced EF have largely been untested in
issions
the mean BW in patients without events, at the clinic visit prior to an event, at a
ean values are plotted with standard error from the mean. p Values are for
roduced, with permission, from Blair et al. (23).
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Rehospitalization for Heart Failure January 29, 2013:391–403patients with preserved EF, the active management of
comorbidities may be even more important in this popula-
tion (57). Although rehospitalizations due to congestion are
frequent in these patients, a significant number of readmis-
sions are related to cardiac and noncardiac comorbidities
(57). Optimization of heart rate and blood pressure is
important because both can contribute to diastolic abnor-
malities resulting in pulmonary congestion.
Transition of care and post-discharge period (vulnerable
phase). The immediate post-discharge period has been
termed the “vulnerable phase” of HHF (22). Increased
congestion, deteriorating renal function, and worsening
neurohormonal abnormalities contribute to early readmis-
sion in a subset of patients (22). An early post-discharge
visit has been recommended for all patients (40,58), but it is
uncertain which subset of patients should be targeted and
what should be evaluated/treated during this visit (31).
Although the majority of studies have focused on fluid
management and intensive monitoring strategies (59–62), a
more comprehensive approach is needed.
The early post-discharge visit is part of an ongoing
assessment of patient, substrate, and precipitating and
amplifying factors (63). Such evaluations may continue after
General Considerations Regarding Gapsin Transiti of Care in Heart FailureTable 5 Gener l Conside ations Regarding Gapsin Transitions of Care in Heart Failure
Physician assessment
Failure to recognize worsening clinical status prior to discharge from the
hospital
Failure to identify or address comorbid conditions (underlying depression,
anemia, hypothyroidism, and so on)
Medication errors and adverse drug events
Failure to recognize worsening clinical status prior to discharge from the
hospital
No or inadequate provision of education to patient and family/caregiver
Failure to clarify whether patient and caregiver understood instructions and
plan of care
Failure to address prior nonadherence in self-care, diet, medications,
therapies, daily weights, follow-up, and testing
Providing information on broad themes without details on how to make it
work for the individual patient based on lifestyle, economic constraints,
social support, and other patient or process factors
Handoff communication
Lack of communication resulting in primary care provider not knowing patient
admitted
Poor communication of the care plan to the nursing home team, home
healthcare team, primary care physician, or family caregiver
Discharge instructions missing, inadequate, incomplete, or illegible
Lack of understanding by the healthcare receiver of information regarding
heart failure medical and self-care management
Hospital to home and discharge planning
Medication errors
Patient lack of adherence to self-care, e.g., medications, therapies, diet
(sodium restriction), and/or daily weights because of poor understanding or
confusion about needed care, how to get appointments, or how to access
or pay for medications
No follow-up appointment or follow-up too long after hospitalization
Failure to provide phone number of physician/nurse patient should call if heart
failure worsensdischarge through multiple avenues, including a follow-up nphone call, visiting nurses, and an office visit during the
vulnerable early-discharge period, telemonitoring, and home
weight monitoring (21,31). Office visits should further opti-
mize short-term diuretic strategies, reassess and re-evaluate
medication regimens, monitor signs and symptoms of HF
including measurement of natriuretic peptides, renal function
and body weight, and continue to explore new cardiac and
noncardiac targets for intervention (Table 6).
Ambulatory hemodynamic monitoring with implanted sen-
sors has the potential to provide an early warning of decom-
pensation and to facilitate patient management by guiding
medication titration based on reliable physiological data (64).
he role of patient and family. The patient and patient’s
amily may play a critical role in bridging the transition from
ospital to home. Patients and their support network need to
nderstand their disease and the importance of complying with
ecommended medications, interventions, and lifestyle changes
activity, diet, sodium restriction). The patient is uniquely
ituated to closely monitor his/her general health status and to
etect early signs of worsening HF. Seeking appropriate early
edical attention in the outpatient setting may avoid unnec-
ssary readmissions. The patient should be aware that partial or
otal recovery of LV function is possible and that HF is not
lways a progressive and fatal condition when properly treated
47). Further data are required to help define the true adjunc-
ive role of support networks in HF management.
team-based approach. The management for each patient
s determined by the patient profile including goals of care,
ocioeconomic circumstances, educational background, and
upport network. Palliative options should be addressed in
hose with end-stage HF. The need to provide affordable
edications and recommend a feasible diet is important.
The complex medical, social, and economic factors con-
ributing to high readmission rates in HHF necessitate an
ntegrated team approach. The patient, primary care physi-
ian, hospital physician, cardiologist, other specialty care
hysicians (e.g., nephrologist, pulmonologist, and endocri-
ologist), pharmacist, nurse, family, social worker, and
ealth educator all provide valuable contributions. Rich et
l. (65) observed that a nurse-directed, multidisciplinary
ntervention reduces hospital admissions in elderly patients
ith HF. Koelling et al. (66) reported that a 1-h, nurse
ducator–delivered teaching session at the time of discharge
esulted in improved clinical outcomes. OPTIMIZE-HF
emonstrated that an increase in adherence to guideline-
ecommended therapies resulted in reduction of a post-
ischarge rehospitalization. Novel initiatives such as the
ospital to Home program of the American College of
ardiology and Institute for Healthcare Improvement, with
goal to reduce all-cause readmission after HF hospitaliza-
ion by 20% by 2012, and the Target: Heart Failure
rogram of the American Heart Association may improve
he transition from inpatient to outpatient care and catalyze
arly post-discharge physician contact.
voiding unnecessary admissions. At present, there are
o standard admission criteria. The acuity at presentation
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January 29, 2013:391–403 Rehospitalization for Heart Failuremay have changed in the last decade because the majority of
patients with HHF have underlying chronic HF and are
receiving evidence-based therapies. In fact, recent registries
show that the rate of pulmonary edema and cardiogenic
shock is extremely low. It is possible that a significant
number of patients presenting to the emergency department
(ED) for worsening congestion may be manageable in an
observation unit with a planned outpatient visit rather than
hospitalization. For these patients, an early follow-up visit
can be as beneficial as hospital admission (67,68).
Performance Measures: Raising the Bar
Although hospitals across the United States are meeting
core measures outlined by the Centers for Medicare and
Figure 5 A Mechanistic Approach to HHF
Assessment and targeted implementation of evidence-based therapy in hospitalize
but dysfunctional myocardium. ACE-I  angiotensin-converting enzyme inhibitor; AF
blocker; CABG  coronary artery bypass grafting; CAD  coronary artery disease;
Hydral  hydralazine; ICD  implantable cardioverter-defibrillator; ISDN  isosorbi
nance imaging. Reproduced, with permission, from Ambrosy et al. J Cardiovasc MeMedicaid Services in recent years, the rates of rehospital-ization have remained relatively unchanged or only slightly
decreased (69). Recent updated American College of Car-
diology Foundation/American Heart Association perfor-
mance measures for HHF patients now include the use of
beta-blockers and scheduling the follow-up outpatient visit
(40). It remains to be seen whether the implementation of
this follow-up visit performance measure will reduce the
rehospitalization rate.
Is 30-Day HF Rehospitalization
the “Right” Target?
Current national improvement initiatives and perfor-
mance measures are focusing on early rehospitalizations
for HF. Since July 2009, there has been mandatory
ents with heart failure (HHF). *Select patients. **Investigational agents. #Viable
ial fibrillation; AHFS  acute heart failure syndrome; ARB  angiotensin receptor
chronic resynchronization therapy; ESC  European Society of Cardiology;
itrate; JVP  jugular venous pulse; LV  left ventricle; MRI  magnetic reso-
gerstown) 2011;12:258–63.d pati
 atr
CRT 
de din
d (Hareporting of 30-day readmission rates for HF by nongov-
; ICD 
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Rehospitalization for Heart Failure January 29, 2013:391–403ernmental hospitals (70,71). However, the 30-day read-
mission may be problematic as a performance measure
because risk-adjustment models have poor discrimination
and do not take into account the competing risk of
mortality. Furthermore, readmission early after hospital
discharge may be influenced, not just by quality of care,
but by more “fixed” factors, including social support,
geographic location, and socioeconomics (72). There is
also a potential disconnect between early readmission and
short-term post-discharge mortality. Because patients
who die early after hospitalization cannot be readmitted,
there is a poor correlation between 30-day mortality and
30-day readmission in most hospital centers (73). High
Components of Early Post-Discharge Follow-UpTable 6 Components of Early Post-Discharg
Action
Education
Diet
Exercise
Medications (benefits, side effects)
Weight monitoring
Detection and treatment of worsening symptoms
Assessment of compliance
Medical therapy
Nonpharmacological prescriptions (diet, exercise,
weight monitoring)
Assessment of prognostic variables
Clinical
Signs of congestion: pulmonary rales,
jugular venous congestion, hepatomegaly,
peripheral edema
Blood pressure
Heart rate
Orthostatic test
Valsalva maneuver
ECG
QRS duration, indication to CRT
Atrial fibrillation, tachyarrhythmias
Laboratory examinations
Myocardial viability*
Natriuretic peptides
Renal function and electrolytes
Anemia and/or iron deficiency
Devices for fluid status monitoring
Optimization of medical treatment
Changes in diuretic doses according to fluid status
Initiation or up-titration of evidence-based therapies
(renin-angiotensin-aldosterone antagonists,
beta-blockers, digoxin)
CRT when indicated
ICD when indicated
Coronary revascularization when indicated
Other surgical procedures (e.g., mitral valve surgery)
*Viable but potentially salvageable myocardium. Reproduced, with pe
CRT  cardiac resynchronization therapy; ECG  electrocardiogram
support effect; 0  not applicable.or stable rates of 30-day readmission may reflect success-ful efforts to drive down post-discharge mortality. This
hypothesis is supported by data demonstrating different
predictors of early readmission and early mortality.
Additionally, even in a well-treated population with a few
clinical comorbidities, a substantial number of patients with
HF (with reduced EF) are rehospitalized for reasons not
directly related to HF (5). Most current post-discharge
efforts focus on managing congestion and close hemody-
namic monitoring. Although these are important goals,
broader strategies to focus on HF-related comorbidities and
patient-centered management may be necessary.
Taken together, these findings suggest that 30-day read-
mission may not be an ideal metric and should not be the
low-Up
Expected Outcomes
vention of Fluid
Overload
Improvement in
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January 29, 2013:391–403 Rehospitalization for Heart Failuretions are “bad,” because these provide additional opportu-
nities to implement further therapies, improve patient
education, or establish clearer follow-up care strategies (73).
Readmission should also not be utilized as a surrogate for
mortality.
Trials in Patients Hospitalized for HF
Trials in HHF patients have been classified into stages A, B,
and C (10). Several drug trials have been conducted in HHF
atients without much success (8). Negative results could
elate to the drug itself, to poor selection of a specific target
atient population most likely to benefit, or to trial execu-
ion (74). Given the global nature of HHF trials, geograph-
cal variations in patient population or standards of care may
lso have contributed to negative results. However, the main
roblem with the prior trials is that they have exclusively
ocused on short-term therapy during hospitalization (stage
and B trials) to improve early symptoms that are already
arkedly improved by standard therapy (75). Because the
rimary problem remains high post-discharge event rates,
rials should focus on therapies initiated during hospitaliza-
ion or soon after that are continued post-discharge (76).
onclusions
igh hospital readmission rates for HF persist despite the
ajor advances in management of chronic HF. It should also
e recognized that a significant number of those readmissions
ccur in patients with HFpEF for which there is no evidence-
ased therapy. This represents a truly unmet need. Strategies to
educe early readmission rates need to primarily target conges-
ion by reducing keep intravascular volume. Early assessment
f clinical deterioration and close monitoring of signs and
ymptoms of congestion are critical in the post-discharge
eriod. Furthermore, clinicians must strive to treat beyond
linical congestion by addressing comorbidities, precipitating
actors, and social circumstances that contribute to worsening
F. This necessitates a mechanistic and comprehensive ap-
roach in terms of patient assessment (e.g., substrate and
nitiating and amplifying factors), time scale of intervention
e.g., ED, inpatient, vulnerable phase assessment, and regular
ollow-up), and team development (patient, family, hospitalist,
rimary physician, cardiologist, nurse, pharmacist, social
orker, and health educators). It remains to be seen how efforts
imed at reducing 30-day readmission rates will impact long-
erm outcomes. More registry and trial data with long-term
ollow-up are necessary to better understand the clinical course
f HHF leading to readmission and to investigate interven-
ions that lead to better outcomes. It will also be important to
evelop alternatives for admissions such as therapies in the ED
ith early follow-up or in an observation unit. It is realistic to
educe rehospitalization rates, but this will require integration
f these efforts on a clinician, hospital, and system level to
mprove overall outcomes.Reprint requests and correspondence: Dr. Mihai Gheorghiade,
Center for Cardiovascular Innovation, Northwestern University,
Feinberg School of Medicine, 645 North Michigan Avenue, Suite
1006, Chicago, Illinois 60611. E-mail: m-gheorghiade@
northwestern.edu
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